6,14-Endoethenotetrahydrooripavine
Chemical compound
6,14-Endoethenotetrahydrooripavine is a chemical compound that belongs to the class of opioids. It is a derivative of thebaine, an alkaloid found in the opium poppy (Papaver somniferum). This compound is of interest in the field of medicinal chemistry due to its potential pharmacological properties.
Chemical Structure[edit | edit source]
6,14-Endoethenotetrahydrooripavine is characterized by its complex polycyclic structure. The compound features a bridged bicyclic system, which is a common motif in many opioid compounds. The presence of the "endoetheno" bridge is a distinctive feature that influences the compound's binding affinity and activity at opioid receptors.
Synthesis[edit | edit source]
The synthesis of 6,14-Endoethenotetrahydrooripavine typically involves the chemical modification of thebaine. Thebaine itself is extracted from the opium poppy and serves as a precursor for many semi-synthetic opioids. The synthesis process involves several steps, including the formation of the endoetheno bridge, which is crucial for the compound's unique properties.
Pharmacology[edit | edit source]
6,14-Endoethenotetrahydrooripavine acts on the opioid receptors in the central nervous system. These receptors are part of the G protein-coupled receptor family and are involved in modulating pain, mood, and reward. The compound's interaction with these receptors can lead to analgesic effects, making it a potential candidate for pain management therapies.
Potential Applications[edit | edit source]
Due to its opioid activity, 6,14-Endoethenotetrahydrooripavine is studied for its potential use in developing new analgesic drugs. Researchers are interested in its ability to provide pain relief with potentially fewer side effects compared to traditional opioids. However, like other opioids, there is a risk of addiction and abuse, which is a significant consideration in its development.
Safety and Regulation[edit | edit source]
As with many opioid compounds, the use of 6,14-Endoethenotetrahydrooripavine is subject to strict regulatory controls. Its potential for abuse and addiction necessitates careful monitoring and regulation by health authorities. Research into its safety profile is ongoing to better understand its effects and potential risks.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD